Study of 99mTc-annexin V uptake in apoptotic cell models of Parkinson's disease

Nuclear Medicine Communications

Volumn 28, Issue 12, 2007, Pages 895-901

  Cao, Wei ^a   Huang, Jinsha ^a   Wu, Jiyuan ^a   Cao, Guoxiang ^a   He, Yong ^a   Hu, Dan ^a   Sun, Shenggang ^b   An, Rui ^b   Zhang, Yongxue ^b  

^a UNION HOSPITAL   (China)

^b 1st Hospital   (China)

Author keywords

Annexin V; Apoptosis imaging radioligand binding assay; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; HYDRAZINONICOTINAMIDE ANNEXIN V TC 99M; NICOTINAMIDE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; LIPOCORTIN 5; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M HYNIC ANNEXIN V;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; EARLY DIAGNOSIS; FEASIBILITY STUDY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; RAT; SCATCHARD PLOT; ANIMAL; CELL STRAIN; METABOLISM; NERVE CELL; PATHOLOGY; SCINTISCANNING;

ANIMALS; ANNEXIN A5; APOPTOSIS; NEURONS; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PC12 CELLS; RADIOPHARMACEUTICALS; RATS;

EID: 37349110028     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1ac9a     Document Type: Article

References (39)

1. Lev N, Melamed E, Offen D. Apoptosis and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:245-250.
2. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184:39-51.
3. 125I-annexin V. Nucl Med Commun 2006; 27:81-89.
4. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 2004; 31:469-474.
5. Ohtsuki K, Akashi K, Aoka Y, Blankenberg FG, Kopiwoda S, Tait JF, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 1999; 26:1251-1258.
6. 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol Med 2005; 111:363-380.
7. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med 2005; 46:2035-2050.
8. 99mTc annexin V imaging of neonatal hypoxic brain injury. Stroke 2000; 31:2692-2700.
9. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinase-annexin V chimeras. Construction, expression, and characterization of recombinant proteins. J Biol Chem 1995; 270:21594-21599.
10. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996; 88:1873-1880.
11. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990; 31:2022-2028.
12. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95:6349-6354.
13. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991; 208:273-286.
14. Watanabe Y, Himeda T, Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med Sci Monit 2005; 11:RA17-RA23.
15. Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA 1983; 80:4119-4123.
16. Rao LV, Tait JF, Hoang AD. Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. Thromb Res 1992; 67:517-531.
17. van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CP, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J 1994; 302(pt 1):305-312.
18. 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001; 16:73-83.
19. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334:71-76.
20. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42:1142-1146.
21. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991; 18:275-278.
22. Jellinger KA. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2003; 74:1005-1006.
23. Burke RE, Kholodilov NG. Programmed cell death: does it play a role in Parkinson's disease? Ann Neurol 1998; 44:S126-S133.
24. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137:120-123.
25. Vermes I, Steur EN, Reutelingsperger C, Haanen C. Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause. Mov Disord 1999; 14:1008-1010.
26. Bosman FT, Visser BC, van Oeveren J. Apoptosis: pathophysiology of programmed cell death. Pathol Res Pract 1996; 192:676-683.
27. Peker C, Sarda-Mantel L, Loiseau P, Rouzet F, Nazneen L, Martet G, et al. Imaging apoptosis with (99m)Tc-annexin-V in experimental subacute myocarditis. J Nucl Med 2004; 45:1081-1086.
28. 99mTc-labeled annexin V. J Nucl Med 2004; 45:1536-1541.
29. 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J Nucl Med 2004; 45:309-331.
30. Mari C, Karabiyikoglu M, Goris ML, Tait JF, Yenari MA, Blankenberg FG. Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V. Eur J Nucl Med Mol Imaging 2004; 31:733-739.
31. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004; 31:887-919.
32. 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med 2003; 44:947-952.
33. Andree HA, Reutelingsperger CP, Hauptmann R, Hemker HC, Hermens WT, Willems GM. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem 1990; 265:4923-4928.
34. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 1989; 264:7944-7949.
35. Anglade P, Vyas S, Hirsch EC, Agid Y. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 1997; 12:603-610.
36. Kingsbury AE, Mardsen CD, Foster OJ. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 1998; 13:877-884.
37. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997; 150:119-131.
38. Wullner U, Kornhuber J, Weller M, Schulz JB, Loschmann PA, Riederer P, et al. Cell death and apoptosis regulating proteins in Parkinson's disease - a cautionary note. Acta Neuropathol (Berl) 1999; 97:408-412.
39. Kosel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl) 1997; 93:105-108.